期刊
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
卷 68, 期 -, 页码 89-94出版社
INFORMA HEALTHCARE
DOI: 10.1080/00365510802150158
关键词
acute kidney injury; acute renal failure; biomarker; chronic kidney disease; contrast nephropathy; kidney transplantation; lipocalin; nephrotoxicity
资金
- NHLBI NIH HHS [R01 HL 08676] Funding Source: Medline
- NIDDK NIH HHS [R21 DK 070163, R21 DK070163-02, R01 DK069749, R01 DK 53289, R01 DK069749-04, R21 DK070163, R01 DK053289] Funding Source: Medline
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069749, R21DK070163, R01DK053289] Funding Source: NIH RePORTER
The incidence of both acute kidney injury (AKI, previously referred to as acute renal failure) and chronic kidney disease (CKD) is reaching epidemic proportions. In both situations, early intervention can significantly improve the prognosis. However, the paucity of early, predictive, non-invasive biomarkers has impaired our ability to institute potentially effective therapies for these common clinical conditions in a timely manner. The current status of one of the most promising novel biomarkers, namely neutrophil gelatinase-associated lipocalin (NGAL), is presented in this review. The evidence for the role of NGAL measurements in a variety of clinical situations leading to AKI (cardiac surgery, kidney transplantation, contrast nephropathy, haemolytic uraemic syndrome and in the intensive care setting) or to CKD (lupus nephritis, glomerulonephritides, obstruction, dysplasia, polycystic kidney disease, IgA nephropathy) is explored. The emerging utility of standardized clinical platforms for reliable measurement of NGAL in plasma (Triage (R) NGAL Device; Biosite Incorporated) and urine (ARCHITECT (R) analyzer; Abbott Diagnostics) is also discussed. It will be important in future studies to validate the sensitivity and specificity of NGAL concentration measurements in clinical samples from large cohorts and from multiple clinical situations. Such studies will be facilitated by the anticipated widespread availability of standardized commercial tools in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据